Extracellular serine protease
AssigneeBoard of Trustees of the University of Arkansas
InventorsTimothy J. O'Brien, Lowell J. Underwood
Life of this patent
Estimating the term…
Abstract
The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention.
Claims27
Isolated DNA encoding a Tumor Antigen Derived Gene-14 (TADG-14) protein selected from the group consisting of:
- (a) isolated DNA having the sequence of SEQ ID No. 6;
- (b) isolated DNA which is complementary to the isolated DNA of (a);
- and
- (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code.
Isolated and purified TADG-14 protein coded for by DNA selected from the group consisting of:
- (a) isolated DNA having the sequence of SEQ ID No. 6;
- and
- (b) isolated DNA differing from the isolated DNA of (a) in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-14 protein.
A method of vaccinating an individual against TADG-14 protein, comprising the step of:
- inoculating an individual with a TADG-14 protein or fragment thereof, wherein said TADG-14 protein or fragment thereof lack TADG-14 protease activity, wherein said inoculation with said TADG-14 protein or fragment thereof elicits an immune response in said individual, thereby vaccinating said individual against TADG-14.
A method of producing activated immune cells directed toward TADG-14, comprising the steps of:
- exposing immune cells to a TADG-14 protein or fragment thereof, wherein said TADG-14 protein or fragment thereof lacks TADG-14 protease activity, wherein said exposure to said TADG-14 protein or fragment thereof activates said immune cells, thereby producing activated immune cells directed toward TADG-14.
An immunogenic composition, comprising a n immunogenic fragment of a TADG-14 protein and an appropriate adjuvant.
An oligonucleotide having a sequence of SEQ ID No. 72.
Dependencies are inferred from the claim text.